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Proteolysis-Targeting Chimeras (PROTACs) are heterobifunctional small-molecules that can
promote the rapid and selective proteasome-mediated degradation of intracellular proteins
through the recruitment of E3 ligase complexes to non-native protein substrates. The cata-
lytic mechanism of action of PROTACs represents an exciting new modality in drug discovery
that offers several potential advantages over traditional small-molecule inhibitors, including
the potential to deliver pharmacodynamic (PD) efficacy which extends beyond the detectable
pharmacokinetic (PK) presence of the PROTAC, driven by the synthesis rate of the protein.
Herein we report the identification and development of PROTACs that selectively degrade
Receptor-Interacting Serine/Threonine Protein Kinase 2 (RIPK2) and demonstrate in vivo
degradation of endogenous RIPK2 in rats at low doses and extended PD that persists in the
absence of detectable compound. This disconnect between PK and PD, when coupled with
low nanomolar potency, offers the potential for low human doses and infrequent dosing
regimens with PROTAC medicines.
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Targeted degradation of intracellular proteins usingProteolysis-Targeting Chimeras (PROTACs) represents arapidly emerging technology with applications in both
drug discovery and chemical biology1–3. PROTACs are hetero-
bifunctional molecules designed to simultaneously bind to
a target protein and to an E3 ligase complex to promote the
formation of a ternary complex and the transfer of ubiquitin to
surface lysine residues on the target protein, tagging it for
degradation by the proteasome. Once the ubiquitin transfer event
has occurred, a PROTAC molecule is available to form a new
ternary complex, thus acting in a catalytic manner. This
mechanism of action contrasts with traditional small-molecule
inhibitors, where high levels of sustained occupancy are fre-
quently required to elicit the desired pharmacology. Although
PROTAC technology was first described nearly 20 years ago4,
there has been a dramatic increase in interest and activity cata-
lysed by improvements in the embedded E3 ligase binders5–8
which have delivered higher cell permeability. These improve-
ments have increased cellular protein degradation potency of
PROTACs from the high micromolar range to the low or even
sub-nanomolar range9–12.
While PROTAC technology represents an attractive approach to
protein knock-down in vitro and in vivo as part of fundamental
target biology investigations, its potential to deliver a new class of
small-molecule degrader therapeutics could be transformative. The
PROTAC event-driven catalytic mechanism of action of PRO-
TACs can deliver potent cellular effects, and there may be addi-
tional advantages in cases where protein synthesis is slow. In these
cases, PROTACs may enable a disconnect between pharmacoki-
netics (PK) and pharmacodynamics (PD) to provide extended
duration of in vivo efficacy long after the PROTAC has been
cleared from systemic circulation. This PK/PD disconnect may
provide novel opportunities to develop medicines with low human
doses and infrequent dosing regimens, although to date this
potential has only been anticipated13 with no rigorous preclinical
in vivo data available to support this hypothesis to our knowledge.
Receptor-Interacting Serine/Threonine Protein Kinase 2
(RIPK2, also known as RIP2, RICK, CARDIAK, and CARD3)
sits downstream of the pattern recognition receptors NOD1 and
NOD2. NOD1 recognises the intracellular presence of the pep-
tidoglycan fragment D-glutamyl-meso-diaminopimelic acid
(iE-DAP) found predominantly in Gram-negative bacteria,
whereas NOD2 recognises the muramyl dipeptide (MDP) com-
ponent of peptidoglycans found in most bacteria14,15. Activation
of this pathway results in transcriptional activation of multiple
inflammatory cytokine genes, and its dysregulation is associated
with several immune disorders such as inflammatory bowel dis-
ease (IBD)16,17 as well as severe pulmonary sarcoidosis18 and
multiple sclerosis19. Protein turnover data for RIPK2 in primary
immune cells generated via dynamic Stable Isotope Labeling with
Amino Acids in Cell Culture (SILAC) labeling experiments
indicates a half-life of generally ~50 h or longer20,21 (Supple-
mentary Fig. 1). Considering this prolonged half-life rate, we
viewed RIPK2 as a suitable candidate protein to explore the
potential for an extended PD response from PROTAC-mediated
target degradation.
We report here a series of optimised PROTACs that promote
the in vivo degradation of the kinase RIPK2 at low doses with
RIPK2 degradation that persists beyond the detectable PK pre-
sence of the compound. Additionally, they inhibit inflammatory
cytokine production in human primary cells and in inflamed
colon tissue biopsies taken from ulcerative colitis (UC) and
Crohn’s disease (CD) patients. Further, we demonstrate that the
RIPK2-degrading PROTACs act selectively at a proteomic level.
Results
We have previously disclosed the potent and selective von
Hippel-Lindau (VHL) based RIPK2 PROTAC 1 utilising an
aminobenzothiazole-quinoline based RIPK2 binder9. To assess
the effect of varying the E3 ligase binder, we prepared the
analogous PROTACs 2 and 3 where the VHL binder was replaced
by inhibitor of apoptosis (IAP) and cereblon-based E3 ligase
recruiting moieties, respectively (Fig. 1).
The compounds were incubated with THP-1 cells for 18 h after
which RIPK2 levels were determined using a capillary-based
immunoassay (n= 3). All three PROTACs potently degraded
RIPK2 in a concentration dependent manner (Fig. 1). The IAP-
based PROTAC 2 was found to have a log half-maximal degra-
dation concentration (pDC50) value of 9.4 ± 0.1 and was more
potent than either the equivalent VHL based PROTAC 1 (pDC50
8.7 ± 0.1) or the cereblon based PROTAC 3 (pDC50 8.6 ± 0.4).
Despite the sub-nanomolar degradation potency of PROTAC 2, it
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Cereblon based RIPK2 PROTAC 3
IAP based RIPK2 PROTAC 2
VHL based RIPK2 PROTAC 1
Fig. 1 PROTAC molecules potently degrade RIPK2 in THP-1 cells. We observed the degradation of RIPK2 in THP-1 cells relative to DMSO control upon
treatment with analogous RIPK2 PROTACs employing VHL (1), IAP (2), and cereblon (3) E3 ligase recruiting moieties measured via a capillary-based
immunoassay after 18 h treatment (n= 3).
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has substantially weaker RIPK2 binding, with an IC50 of 10 nM in
a RIPK2 fluorescence polarisation binding assay. This dis-
crepancy between the in vitro RIPK2 degradation and binding
potency provides possible evidence for a catalytic mechanism of
action of this compound.
While RIPK2 can be efficiently degraded by VHL, cereblon,
and IAP based PROTACs and it is highly likely PROTACs
based on all three ligases could be further optimized, we deci-
ded to focus on IAP based RIPK2 PROTACs for further studies.
Consistent with PROTAC 2 being a potent degrader of RIPK2
in THP-1 cells, this compound also inhibited MDP-induced
TNFα release in a human whole blood assay (pIC50= 7.95 ± 0).
Nevertheless, the microsomal turnover of 2 in both rat
and human microsomes was found to be very high (11 and
29 mL/min/g liver in rat and human microsomes, respectively),
suggesting that this compound would have limited utility as an
in vivo tool molecule. Additionally, this compound was found
to have poor solubility as determined via a high-throughput
precipitation assay using chemiluminescent nitrogen-specific
detection (CLND)22,23. We hypothesised that reducing the
lipophilicity of 2 would have a beneficial impact on reducing
microsomal turnover and would also increase its solubility.
The lipophilicity of test compounds was accessed via the
ChromLogD7.4 high-throughput chromatographic method, and
PROTAC 2 was found to have a ChromLogD7.4 of 6.1.
The ChromLogD7.4 technique affords a greater dynamic range
than is feasible with the classical octanol-water method
although a consequence of the scaling used in this technique is
a positive offset of approximately two log units24.
Development of an initial in vivo RIPK2 PROTAC tool
molecule. The RIPK2-IAP PROTAC 4 (Fig. 2) identified in the
course of our medicinal chemistry optimization program
(manuscript in preparation) is significantly different from 2,
possessing a different RIPK2 binder, IAP ligase binder, and linker.
In human PBMCs, 4 degraded RIPK2 in a time dependent
manner (pDC50= 7.9 ± 0.2, Dmax 69.2 ± 11.5% at 24 h, Supple-
mentary Fig. 2) and inhibited L18-MDP (a synthetic derivative of
MDP)-induced TNFα release (pIC50 8.0 ± 0.5 at 6 h). The inhi-
bition of MDP-induced TNFα release in whole blood by 4 was the
same in both rat and human (pIC50 7.7). A control PROTAC 5
(the enantiomer of PROTAC 4) maintains the RIPK2 binding
potency (RIPK2 FP pIC50 6.7 ± 0.05) but in human PBMCs it
does not degrade RIPK2 and showed more than 10-fold reduced
activity in L18-MDP-induced TNFα release (pIC50 6.5 ± 0.5,
Supplementary Fig. 2). The difference in potencies between
PROTAC 4 and the control PROTAC 5 in the L18-MDP func-
tional assay clearly illustrates the impact of the PROTAC medi-
ated protein degradation.
Both the amino pyrazole-quinazoline RIPK2 binder and the IAP
binder related to LCL-161 reduce the lipophilicity of PROTAC 4,
and when incorporated with the linker shown, demonstrated low
clearance in hepatocytes (<0.80 and <0.45mL/min/g liver in rat
and human liver hepatocytes, respectively).
Globally, these changes reduced the ChromLogD7.4 of 4 to 4.2
and improved the high-throughput CLND solubility to >311 μM.
The low turnover of PROTAC 4 rate in rat hepatocytes was found
to translate into the in vivo setting, where the mean intravenous
clearance in rats was less than a quarter of liver blood flow. This
lower clearance coupled with a large volume of distribution
resulted in an in vivo compound half-life of 6.9 h (Table 1).
The PK profile of compound 4 combined with its in vitro
RIPK2-mediated functional inhibitory potency (pIC50= 7.7 ±
0.05) determined from the inhibition of L18-MDP-stimulated
TNFα release in rat whole blood, suggested that this molecule
would be suitable for the investigation of the PK/PD relationship
resulting from in vivo RIPK2 degradation. Time course experi-
ments were conducted in rats to determine the PK and associated
PD profiles following a single subcutaneous dose; 20 mg/kg
studied over 7 days and three dose levels of 1, 5, and 20 mg/kg
studied over 14 days (Fig. 3).
High levels (>70%) of TNFα inhibition following ex vivo L18-
MDP stimulation in rat blood were observed throughout the
7-day study following administration of a single dose of 20 mg/kg
PROTAC 4, even though endogenous RIPK2 degradation
measured by Western blot was only reduced by ~50% at 8 h
post-dose, which then increased to >80% RIPK2 degradation
when measured at both the 72 h and 168 h time-points
highlighting the time-dependency of degradation (Fig. 3a).
Although compound 4 contains a RIPK2 inhibitor, the in vitro
L18-MDP data for the control PROTAC 5 would suggest that the
high level of TNFα inhibition observed at the 8 h post-dose time
point is mostly driven by the partial degradation of RIPK2 with
only a small contribution from direct inhibition. At the later
time-points, there was sustained RIPK2 degradation and inhibi-
tion of TNFα levels despite the compound levels declining to
below 10 ng/mL, which is below the rat whole blood IC90 value
for inhibition of L18-MDP-stimulated TNFα release. These
data indicate a disconnect between the PK and PD for this
compound, with the efficacy at later timepoints being driven
predominantly by RIPK2 degradation. As the initial study at
20 mg/kg was stopped after 168 h monitoring, a second study was
also conducted with a longer monitoring period to establish the
recovery of RIPK2 levels.
In the follow-up 14-day study (Fig. 3b, c), 40–60% degradation
of RIPK2 was observed across all dose levels at the 8 h time point.
The 20 mg/kg dose level data were consistent with the previous
study. At 72 h post-dose, there was a clear dose-dependent
Fig. 2 Structures for PROTACs 4 and 6 and control PROTACs 5 and 7. We optimized PROTAC 2 to obtain PROTACs 4 and 6, as well as control
compounds 5 and 7 which cannot recruit IAP.
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degradation of RIPK2. The later time point of 240 h showed
recovery of the protein levels which returned to baseline levels for
each dose group. Overall, this data set suggests that the prolonged
PD response is a function of both the PK profile of the compound
and the slow synthesis rate of the target protein. The combined
in vivo data set for compound 4 is consistent with RIPK2
possessing a half-life of approximately 2–3 days in rat.
In vitro characterisation of the optimised RIPK2 PROTAC 6.
While 4 possesses improved physicochemical properties com-
pared to 2 and a rat PK profile supportive of in vivo efficacy,
the modest binding potency of 4 (RIPK2 pIC50= 6.6 ± 0.02)
and cellular degradation potency (pDC50= 7.9 ± 0.2, Dmax 69.2 ±
11.5% at 24 h) impacts the dose required to deliver high levels of
in vivo degradation of RIPK2. To address this limitation, further
medicinal chemistry optimisation resulted in the identification of
PROTAC 6 (Fig. 2), which contains an additional methylene
spacer at the junction of the RIPK2 binding moiety and the lin-
ker, as well as a modified IAP binder. Crucially, the additional
methylene group increased the RIPK2 inhibitory potency (pIC50
8.0 ± 0.05) more than 10-fold, which translated into significantly
improved cellular degradation potency in human PBMCs (see
Fig. 4) and human whole blood potency (pIC50 8.5 ± 0.07). Low
turnover in hepatocytes was maintained in both rat and human
(<0.8 and <0.45 ml/min/g liver, respectively), along with moder-
ate lipophilicity and solubility (Chrom LogD7.4 3.6, CLND solu-
bility 346 µM). In vivo rat PK data for 6 demonstrated reduced
in vivo clearance compared to 4, which resulted in an extended
half-life of 16 h for this compound (Table 1). Compound 6 also
demonstrated a large window (>1000 fold) between RIPK2
degradation and the autoubiquitination-mediated degradation of
cIAP1 in human PBMCs, and no effects on cell viability were
detected except at concentrations >1 µM (Supplementary Fig. 3).
PROTAC 6 produced a concentration and time dependent
decrease in RIPK2 protein levels in human PBMCs (Fig. 4a) such
that the pDC50 and maximal degradation (Dmax) increased with
longer incubation times, and a pDC50 of 9.4 ± 0.2 and Dmax of
94.3 ± 3.2% was determined for 6 following 24 h incubation.
PROTAC 6 completely inhibited TNFα, IL1β, IL-6, and IL-10
release following L18-MDP-stimulation with pIC50 values >8.8,
but only partially inhibited IL-8 release (pIC50= 8.5 and Imax ~
50%; Fig. 4b). Since the in vitro activity of this compound is likely
due to a combination of degradation and direct inhibition of the
protein, the impact of RIPK2 degradation on the in vitro activity
of 6 was assessed using an E3 ligase inactive control PROTAC 7
(the enantiomer of 6) which possesses the same RIPK2 binder but
an inactive E3 ligase recruiting moiety. In contrast to 6, control
PROTAC 7 did not significantly reduce RIPK2 protein levels
(Fig. 4c) but was still found to inhibit TNFα release upon L18-
MDP treatment with ~30-fold reduced potency (pIC50= 7.8 ±
0.2) and no significant difference in Imax value (Fig. 4d).
b)
c)
a)
Fig. 3 Pharmacokinetic and pharmacodynamic properties of PROTAC 4 in
rats. a Combined plot showing the relative time profiles for the
pharmacokinetics and corresponding pharmacodynamics for PROTAC
4 after SC dosing at 20mg/kg. b RIPK2 levels over time compared to
individual animal pre-dose levels after SC dosing at 1, 5 and 20mg/kg. c Rat
exposure profiles for PROTAC 4. Data points are shown as mean ± s.e.m.
(n= 5).
Table 1 Data for PROTACs 4 and 6 and control PROTACs 5 and 7 showing biochemical potency, DC50, MDP challenge assay
potency as well as rat intravenous PK parameters.
Cpnd RIPK2 FP
pIC50 ± SEM (n)
hPBMC pDC50 /Dmax ±
SEM, 24 h (n= 3)
hPBMC MDP
pIC50 ± SEM, 6 h
(n= 3)
hWB MDP
pIC50 ± SEM (n)
rWB MDP
pIC50 ± SEM (n)
Rat Clearance
mL/min/kg
Rat
Vdss L/kg
Rat
T½h
4 6.6 ± 0.02 (8) 7.9 ± 0.2/69.2 ± 11.5% 8.0 ± 0.5 7.7 ± 0.05 (4) 7.7 ± 0.16 (4) 18 11 6.9
5 6.7 ± 0.05 (12) Non-degrader 6.5 ± 0.5 – – – – –
6 8.0 ± 0.05 (24) 9.4 ± 0.2/94.3 ± 3.2% 9.3 ± 0.03 8.5 ± 0.07 (14) 8.5 ± 0.1 (4) 10 7.6 16
7 8.4 ± 0.09 (4) Non-degrader 7.8 ± 0.2 – – – – –
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Previous studies25,26 have demonstrated that RIPK2 inhibitors
can significantly inhibit spontaneous inflammatory cytokine
release from inflamed intestinal tissue taken from UC and CD
patients in an ex vivo culture system, supporting the hypothesis
that RIPK2 kinase may be a key node in the signaling network
connecting multiple pattern recognition receptors. Accordingly,
PROTAC 6 was also tested in an ex vivo culture system using
human biopsies taken from inflamed intestinal tissue of CD and
UC patients (Fig. 4e, f and Supplementary Fig. 4). Upon
treatment with 6, a concentration dependent inhibition of
e)                                                                    f)
c)                                                                    d)
a)                                                                    b)
CD Patient Biopsies UC Patient Biopsies
Fig. 4 PROTAC 6 induces potent degradation of RIPK2 in human PBMCs and inhibits cytokine release in human disease tissue.We tested the effect of
PROTAC 6 on (a) RIPK2 levels at 6 and 24 h and (b) cytokine release following 3h pre-incubation and 3h L18-MDP stimulation in human PBMCs.
Comparison of the effect of PROTAC 6 and negative control PROTAC 7 after 6h on (c) RIPK2 and (d) L18-MDP stimulated TNFα release in human PBMCs.
Data are shown as mean ± s.e.m. (n= 6 except RIPK2 levels at 6h, n= 5). Spontaneous cytokine production from (e) CD and (f) UC disease patient
intestinal biopsies (n= 5–19 per group) upon vehicle (DMSO) treatment (Ctrl) or treated with 1 µM prednisolone (P) or with increasing concentrations
(0.05–50 nM) of PROTAC 6.
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spontaneous IL-1β, IL-6, and TNFα release was observed, with a
maximal effect obtained at 50 nM analogous to that achieved with
1 μM prednisolone. PROTAC 6 was equally effective at inhibiting
spontaneous cytokine release across CD and UC patient biopsy
samples with IC50 values of ~1–3 nM. RIPK2 protein levels were
also assessed by Western blot upon treatment of the CD and UC
donor colon tissue with PROTAC 6. This revealed a trend of
concentration-dependent RIPK2 degradation compared to both
control and prednisolone groups with a statistically significant
reduction of RIPK2 (p < 0.01) observed in the UC biopsy group
treated with 50 nM of PROTAC 6 although no significant
reduction in RIPK2 levels was observed in the CD biopsy group.
(Supplementary Fig. 4). However, due to the nature and time
course of this assay system, it is not possible to distinguish the
relative contributions of direct inhibition versus protein degrada-
tion to cytokine inhibition.
PROTAC 6 shows in vivo efficacy beyond its detectable pre-
sence. The potency of compound 6 in the rat whole blood
functional L18-MDP challenge assay is pIC50= 8.5 ± 0.1. The PK/
PD profile of this compound was investigated using a dose range
of 0.005–0.5 mg/kg dosed SC in rats over 5 days. We observed
that the single 0.5 mg/kg dose caused a significant reduction in
RIPK2 protein levels, with 53 ± 9% RIPK2 degradation observed
at 6 h post-dose, which increased to 78 ± 5% degradation at
the 48 h time-point (Fig. 5a). This dose produced substantial
inhibition (>70%) of TNFα levels upon ex vivo whole blood L18-
MDP challenge, which was maintained over the duration of the
study (Fig. 5b). The intermediate dose of 0.05 mg/kg did not have
a statistically significant effect on measured levels of RIPK2
protein but significantly inhibited the release of TNFα upon
ex vivo L18-MDP challenge by >60% over the first 48 h; at the
later timepoints the TNFα levels were indistinguishable from
control group. In contrast, the lowest dose of 0.005 mg/kg had no
significant effect on RIPK2 or TNFα levels over the duration of
the study. Blood concentrations of 6 (Supplementary Fig. 5)
remained measurable throughout the study at the 0.5 mg/kg dose,
for the first 24 h at the 0.05 mg/kg dose and for the first 6 h at the
0.005 mg/kg dose.
One of the potential advantages of PROTACs over inhibitors is
the possibility for a cumulative efficacy effect with repeat
compound administration in cases where the target protein is
slowly synthesised in cells. To study this potential effect, once
daily (QD) dosing compared to every 3 days (Q3D dosing were
investigated with different dose levels (Fig. 5c–e). Compound 6
(QD dosing, 0.05 mg/kg/day) inhibited TNFα by ~60% at 6 and
24 h post-dose (measured immediately prior to the second dose)
and progressed to >90% inhibition at the 54 h timepoint, which
was 6 h after the third dose (Fig. 5c). The magnitude of RIPK2
degradation progressed over the study duration reaching >70%
degradation at the last time point. At a higher dose of 0.5 mg/kg/
day, profound inhibition (>90%) of TNFα release was obtained at
the 24 h timepoint which was maintained following the next two
doses (Supplementary Fig. 6). At this dose level, the observed
degradation of RIPK2 increased from ~70% at 24 h to >90% at
the last time point following the third dose. Analysis of terminal
colon samples via Western blot at both doses revealed significant
degradation of RIPK2 (Fig. 5f).
Using the 0.05 mg/kg dose level but dosing Q3D failed to show
this cumulative PD effect (Fig. 5d). Repeating the Q3D dosing
schedule at a higher dose level (0.15 mg/kg/day) produced
maximal inhibition of TNFα at 72 h post dose, immediately
prior to the second dose and 48 h after drug levels had dropped
below the lower limit of quantification (LLQ). This response was
maintained throughout the remainder of the study (Fig. 5e). This
was accompanied by a partial reduction in RIPK2 protein levels
observed 24 h after the first dose, which was maintained with the
subsequent doses.
In vivo L18-MDP administration to rodents results in an
acute inflammatory response characterised by the rapid
production of inflammatory cytokines27. Given the prolonged
duration of PD response observed upon dosing PROTAC 6 in
rats as characterized by inhibition of TNFα release following
ex vivo L18-MDP challenge (Fig. 5), we sought to determine the
PK profile and the kinetics of the PD response produced by a
single dose of PROTAC 6 in blood and tissues (spleen and distal
colon) in rats which received an intravenous dose of L18-MDP
(150 μg/rat). The previously described PROTAC inactive
control 7 was also included at the same dose level as 6
(0.3 mg/kg), since it possesses similar physicochemical proper-
ties and PK as 6. Following L18-MDP administration, dosing of
PROTAC 6 was found to inhibit the release of all tested
inflammatory cytokines across compartments (Fig. 6). Serum
cytokines were profoundly reduced (>75% inhibition) over the
first three days and were significantly suppressed up to 6-10
days post-dose, while animals treated with the E3 ligase inactive
control compound 7 were indistinguishable from the control
animals except at the 72 h time-point, which was unexpected
and inconsistent with the rest of the profile (Fig. 6a–c). Blood
concentrations of 6 and 7 tracked closely and dropped below the
LLQ after 24 h. In the spleen (Fig. 6d–f), the inhibition of TNFα
and IL-8 was short-lived and returned to basal levels by the
third day post-dose, whereas the release of these cytokines was
significantly inhibited for up to six days post-dose in the distal
colon (Fig. 6g–i).
PROTAC 6 degrades RIPK2 with high selectivity. To determine
the degradation selectivity of 6, we conducted studies employ-
ing multiple proteomics techniques across a range of cell
types. Chemoproteomics profiling of 6 with kinobeads28,29
using mixed protein extracts from HEK293, K-562, U-87 MG
cells, and human placenta demonstrated high affinity of this
compound for endogenous RIPK2 (pKdapp= 8.4). Compound 6
was also found to be highly selective, with EPHA6 (pKdapp=
6.8) and PAK4 (pKdapp= 6.4) representing the only kinase off-
targets with quantifiable affinity. No quantifiable affinity was
measured for either RIPK1 or RIPK3 (see Supplementary
data 2 file).
Compound 6 was further characterized by thermal proteome
profiling30,31 in U-87 MG and THP1 cells, measuring dose-
dependent changes in thermal stability across the proteome.
Consistent with the proposed mechanism of action of PROTAC
6, temperature-independent reduction of RIPK2 levels was
observed at concentrations ≥0.1 µM and BIRC2 (cIAP1) levels
were substantially reduced at concentration of 6 of >1 µM
(Fig. 7a). This effect was found to be amplified upon prolonged
incubation time (up to 240min) with this compound. No other
proteins were reproducibly affected in thermal stability or
abundance by 6, underpinning the exquisite selectivity of this
compound.
Having characterized the cellular protein interactors of 6, we
also investigated the proteins degraded by this compound using
the recently described multiplexed proteome dynamics profiling
approach (mPDP)32. This technique can identify degraded targets
through reduced levels in protein pools that were already
present at the time dynamic SILAC labeling was initiated
(mature proteins), as well as in the nascent proteins that were
subsequently synthesised after SILAC labeling was conducted.
U-87 MG or THP-1 cells were treated with PROTAC 6 at
concentrations of 1 nM, 10 nM, 100 nM, and 1 μM, and were
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harvested after 6 and 24 h of treatment. A substantial reduction of
mature RIPK2 protein levels was observed in U-87 MG cells after
6 h in the presence of 1 nM compound 6, with no reduction
observed in any other protein although BIRC2 was not
quantifiable (Fig. 7b). Selective degradation of RIPK2 was also
observed with 10 nM compound 6 after 6 h; an apparent increase
in PTMA (significantly regulated protein in Fig. 7b, c) at this time
was not observed at higher concentrations or at the later 20 h
timepoint. However, we observed a significant decrease in
abundance of mature MAPK14 in addition to RIPK2 following
20 h incubation of both U-87 MG and THP-1 cells with
compound 6 at concentrations ≥0.1 µM (see Supplementary
Fig. 7). There were no changes in the abundance of PAK4, RIPK1
and RIPK3 in these experiments. The abundance of EPHA6 was
not quantifiable. In addition to analysis of the protein extract,
protein kinases were enriched using the kinobeads matrix28. This
enabled investigation of changes in the abundance of kinases with
low expression that would otherwise not be identified in the mass
spectrometric analysis. The selective degradation of RIPK2 at
both 6 and 20 h across both mature and nascent protein was
***
**
e)                                                                                                         f)
a)                                                                                           b)
c)                                                                                          d)
Fig. 5 In vivo dosing of PROTAC 6 in rats caused the degradation of RIPK2 and a decrease in TNFα levels upon ex vivo L18-MDP challenge. We
determined the effect of dosing PROTAC 6 (0.005, 0.05 and 0.5 mg/kg SC) in rats on (a) RIPK2 levels compared to pre-dose levels and (b) TNFα levels
following ex vivo L18-MDP challenge compared to the vehicle control group. Combined PK and PD time profiles are shown for 0.05mg/kg (c) QD and (d)
Q3D and (e) 0.15 mg/kg Q3D administered SC. f Effect of dosing PROTAC 6 (0.05 and 0.5 mg/kg QD SC) in rats on RIPK2 levels in colon compared to
vehicle control group. Data are shown as mean±s.e.m and n= 4–5/group. P values calculated by ANOVA Dunett test comparing control vs. PROTAC
(**P < 0.01, ***P < 0.001).
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observed (Fig. 7d). However, this technique of kinase enrichment
cannot distinguish between a PROTAC 6 mediated decrease in
protein abundance and PROTAC 6 binding to the kinase at the
ATP binding site but not inducing its degradation.
Discussion
An appreciation of the significant opportunities afforded by recent
developments in PROTAC-mediated targeted protein degradation
for both novel therapeutics and tools for chemical biology is clearly
exemplified by the dramatic increase in publications over the last
two years1–3. Many of these reports have presented in vitro studies
that have demonstrated the importance of the ternary complex
between the target protein, the PROTAC, and the E3 ligase com-
plex in determining not only the degradation efficiency, but also
introducing greater degradation selectivity as compared to the
native binding selectivity of the target binding moiety of the
Blood
Spleen
  L18-MDP control                      PROTAC 6                         PROTAC 7
g)                                              h)                                          i)
d)                                              e)                                          f)
a)                                           b)                                          c)
Colon
Fig. 6 In vivo dosing of PROTAC 6 in rats suppressed cytokine release following intravenous L18-MDP challenge. We determined the effect of dosing
PROTAC 6 (0.3 mg/kg SC; black bars) or control PROTAC 7 (0.3 mg/kg SC; gray bars) in rats following intravenous L18-MDP challenge on the cytokine
release in (a–c) blood, (d–f) spleen, and (g–i) colon. Data are plotted as mean ± s.e.m. (n= 5/group), with the timepoints shown indicating the length of
PROTAC/vehicle treatment. This was followed by 2 h L18-MDP challenge at which point the cytokines levels were measured.
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corresponding PROTAC33–36. In the current work, we began with
a highly potent and selective RIPK2 inhibitors already available as a
result of previous RIPK2 lead optimization efforts25,37, and we were
able to quickly demonstrate effective degradation of the target
protein with PROTACs based on these inhibitors. It is noteworthy
that the highly potent cellular degradation of RIPK2 by PROTAC 2
(pDC50= 9.4 ± 0.1) is achieved from a less potent biochemical
RIPK2 IC50 of 10 nM. This is indicative of the advantages that the
catalytic, event-driven pharmacology that PROTACs can deliver
when compared to traditional occupancy-based inhibitors.
The majority of protein degradation targets described to date are
for oncology indications. As expected, much of the reported in vivo
data for PROTACs that degrade these targets has been in mouse
xenograft studies, and while significant tumor regression has been
disclosed in several instances, these studies have generally not
sought to develop a detailed PK/PD understanding38. A recent
report has focused on the in vivo effects of PROTACs across
preclinical species in various tissues, but the relationship of protein
degradation to circulating drug concentrations is not discussed39.
Since we were aware at the outset of this work that RIPK2 had a
long-half life, particularly in primary cells, there was an expectation
that we might observe enduring RIPK2 protein knock-down upon
PROTAC-mediated RIPK2 in vivo degradation.
The first demonstration of this principle was observed with
PROTAC 4 where a single SC administration of 20 mg/kg in rats
produced sustained high levels of RIPK2 degradation and inhi-
bition of ex vivo TNFα release for seven days post-dose despite
drug levels decreasing below 10 ng/mL after 7 days, which
is below the IC90 for 4 in the L18-MDP challenge assay. Addi-
tionally, there was no discernible change in RIPK2 degradation or
TNFα release inhibition between the 3-day and 7-day-timepoints
despite the decline in circulating drug levels. This study clearly
supports one of the anticipated potential advantages of PROTACs
over small-molecule inhibitors by showing that infrequent dosing
regimens are able to provide sustained efficacy in cases where the
protein synthesis rate is slow. Studying the PK/PD response
observed during a longer 14-day-study in rats allowed us to
characterize the synthesis of RIPK2 protein back to basal levels
following drug clearance, which was associated with a decrease in
functional response as expected. This study allowed us to estimate
the in vivo RIPK2 half-life in rat as 2–3 days.
PROTAC 6 is structurally similar to PROTAC 4, although
modifications to the linker afforded significantly increased
binding potency for RIPK2 which translated into improved
degradation potency and subsequent whole blood potency in
both rat and human. The implication of this observation is that
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Fig. 7 Thermal proteome profiling of PROTAC 6 demonstrates selective degradation of RIPK2 in cells. a Thermal proteome profiling heatmap for RIPK2
and BIRC2 (cIAP1) following treatment with PROTAC 6 across a concentration range of 0.001 µM to 1 µM and treatment durations of 0.5, 1.5, and 4 h (blue:
100% protein level, red: below 30%, gray: not identified) b mature proteins levels derived from mPDP profiling of PROTAC 6 at 0.001 µM and 0.01 µM in
U-87 MG cells at 6 h, RIPK2 highlighted in red, orange indicates statistical significant regulation (PTMA) c nascent proteins levels derived from mPDP
profiling of PROTAC 6 at 0.001µM and 0.01 µM in U-87 MG cells at 6 h, RIPK2 highlighted in red, orange indicates statistical significant regulation. d Line
plot for protein dynamics profiling experiments separated for mature and nascent proteins following treatment of PROTAC 6 in U-87 MG cells followed by
kinobeads enrichment of kinases in the cell extract; RIPK2 shown in red.
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the propylene-piperazine moiety may be considered as part of
the RIPK2 binder with only the pyrazine ring constituting a
short linker. Coupling the improved potency of PROTAC 6
with its long exposure in rat and the slow RIPK2 synthesis rate
afforded efficacious in vivo protein degradation at very low
doses. To our knowledge, the repeat dose PK/PD study also
revealed a novel and highly attractive aspect of PROTAC
pharmacology whereby repeated administration of sub-
maximal efficacious doses caused a cumulative increase in
protein degradation of RIPK2 without drug accumulation.
Indeed, for the 0.05 mg/kg group dosed daily, PROTAC 6 Cmax
concentrations never exceeded 15 ng/mL and were approxi-
mately at the LLQ (1 ng/mL) for most of the study. Further
repeat dose studies with a less frequent dosing regimen pro-
vided further insights into the relationship of both dose and
protein synthesis rates on maintaining reduced protein levels
to elicit the PD response. The Q3D dosing of PROTAC 6 at
0.15 mg/kg provides some of the most compelling evidence for
the extended PD response. Following the first dose, drug levels
were maintained above the LLQ for 24 h. Nevertheless, at the
72 h timepoint, prior to the administration of the second dose,
there was clear evidence of persisting RIPK2 degradation and
inhibition of TNFα production in the absence of measurable
drug levels
Overall, the extended in vivo PD responses in both blood and
in tissues that we observed upon event driven PROTAC-mediated
target degradation contrast significantly to the PD typically seen
with traditional non-covalent inhibitors, where the pharmacolo-
gical effect is often dependent on maintaining high levels of
occupancy at trough concentrations. The high Cmax often asso-
ciated with the high dose levels required to achieve the required
exposure can be the cause of unwanted toxicities where selectivity
windows are eroded40. In contrast, by reducing the need for high
Cmax levels to achieve sufficient event driven therapeutic expo-
sure, we postulate that therapeutic efficacy can be achieved with
improved safety for PROTACs that degrade proteins with mod-
erate to slow synthesis rates versus inhibitors.
Modern proteomic techniques can provide deep insights into
compound selectivity in physiologically relevant cellular settings.
For PROTAC 6 this has been achieved through a combination of
kinobeads experiments, thermal proteome profiling and protein
dynamics experiments. While size and molecular complexity have
been implicated in binding promiscuity41 it is clear from these
proteomic experiments that 6 possesses an extremely selective
binding profile with a very small number of off-target interac-
tions. RIPK2 is the only detected degradation target for PROTAC
6 at concentrations below 0.1 µM.
Translation to the clinic represents the current frontier for the
rapidly evolving PROTAC field. We have generated robust data
through the PROTAC-mediated degradation of RIPK2 in rat
in vivo and ex vivo studies, and also in human in vitro PBMCs
and in human ex vivo inflamed biopsies, where we observe
conclusive RIPK2 protein degradation and the inhibition of
disease-relevant cytokine release. These results provide evidence
that RIPK2 degradation may be a feasible approach to disease
modification in CD and UC patients. Data from these biopsies
also provides a useful foundation on which to build human dose
predictions in conjunction with the in vivo efficacy data.
In summary, we have demonstrated how the event-driven,
catalytic PROTAC mechanism of action coupled with slow pro-
tein re-synthesis rates affords opportunities to develop low dose
medicines with infrequent dosing schedules and reduced expo-
sure of drug, which may afford an improved safety window when
compared to traditional inhibitors. We envision that this concept
may become even more important in the future as additional
PROTAC molecules are advanced into the clinic.
Methods
Preparation and characterisation of compounds 1–7 is described in the Supple-
mentary Information.
All animal studies were ethically reviewed and carried out in accordance with
Animals (Scientific Procedures) Act 1986 (United Kingdom) or GSK Institutional
Animal Care and Use Committee (United States of America) and the GSK Policy
on the Care, Welfare and Treatment of Animals. The human biological samples
were sourced ethically, and their research use was in accord with the terms of the
informed consents under an IRB/EC approved protocol.
Cell culture. THP1 cells (ATTC, TIB-202) were cultured at a 3 × 106 cells/ml
density in complete growth medium: RPMI 1640 medium containing GlutaMAX
and 25 mM HEPES and supplemented with 10% fetal bovine serum, 100 U/mL
penicillin and 100 µg/mL streptomycin.
Antibodies. Rabbit anti-RIPK2 (Cell Signaling, 4142), mouse anti-tubulin (Sigma,
T8328), mouse anti-actin (Sigma, A2228), mouse anti-β-actin (Abcam, ab6276),
rabbit anti-β-actin (Abcam, ab8227), mouse anti-vinculin (Abcam, ab129002),
rabbit anti-cIAP1 (Cell Signaling, 7065), rabbit anti-cIAP2 (Cell Signaling, 3130),
mouse anti-XIAP (BD Biosciences, 610717), donkey anti-rabbit IRdye 800CW
(Licor, 926-32213), donkey anti-mouse IRdye 680RD (Licor, 926-68072), 20x anti-
rabbit HRP conjugate antibody (Protein Simple, 043-426), anti-mouse HRP con-
jugate antibody (Protein Simple, 042-205), anti-rabbit HRP conjugate antibody
(ProteinSimple, 042-206).
Microsomal metabolic and hepatocyte stability. Metabolic stability was per-
formed at Cyprotex (UK). Pooled liver microsomes / cryopreserved pooled hepa-
tocytes were purchased from a commercial supplier (BD Biosciences or Corning/
InVitro Technologies).
Microsomal CLint: Liver microsomes (final protein concentration 0.5 mg/mL),
0.05 M phosphate buffer pH 7.4 and test compound (final substrate concentration
0.5 μM; final DMSO concentration 0.25%) were pre-incubated at 37 °C prior to the
addition of NADPH (final concentration 1 mM) to initiate the reaction. The final
incubation volume was 500 μL. A minus cofactor control incubation was included
for each compound tested where 0.05 M phosphate buffer pH 7.4 was added
instead of NADPH (minus NADPH). Each compound was incubated for 0, 5, 15,
30, and 45 min. The control (minus NADPH) was incubated for 45 min only.
Hepatocyte CLint: Williams E media supplemented with 2 mM L-glutamine and
25 mM HEPES and test compound (final substrate concentration 0.5 µM; final
DMSO concentration 0.25%) were pre-incubated at 37 °C prior to the addition of a
suspension of cryopreserved hepatocytes (final cell density 0.5 × 106 viable cells/mL
in Williams E media supplemented with 2 mM L-glutamine and 25 mM HEPES) to
initiate the reaction. The final incubation volume was 500 µL. An appropriate
vehicle control was used. Each compound was incubated for 0, 5, 10, 20, 40, and 60
min. The control (vehicle) was incubated for 60 min.
All incubations were terminated by transferring 50 μL of incubate to 100 μL of
acetonitrile containing internal standard at the appropriate time points. The
termination plates were centrifuged at 2500 rpm for 20–30min at 4 °C to
precipitate the protein. Following protein precipitation, samples were analysed
using quantitative LC-MS/MS. A plot of ln peak area ratio (compound peak area/
internal standard peak area) against time, yielded the gradient of the line.
Subsequently, half-life (t½) and intrinsic clearance (CLint) were calculated using the
equations below:
Elimination rate constant kð Þ ¼ gradientð Þ
Half-life t1=2ð Þ minð Þ ¼ 0:693k
Intrinsic clearance CLintð Þ μL=min=mgproteinð Þ ¼ V ´ 0:693t1=2
where V= Incubation volume (μL)/Microsomal protein (mg).
Calculated intrinsic clearance values of control compounds were compared with
the Cyprotex data library to confirm the appropriate activity of the microsomal/
hepatocyte batch and data acceptance.
In vivo studies. Rat intravenous PK studies: PROTAC 4; Intravenous PK studies
were conducted in male Sprague Dawley (7–10 weeks old at start of dosing) rats,
supplied by Charles River UK Ltd. Rats received a single intravenous (IV) bolus
administration (2 mg/kg, 2 mL/kg, n= 3 rats) formulated as a solution in 5%
DMSO:95% (v/v) 10% (w/v) Kleptose in saline. Serial blood samples were collected
via jugular vein sampling into K2EDTA tubes at various time points up to 24 h
post-dose and diluted with an equal volume of water.
PROTAC 6; Intravenous PK studies were conducted in male Han Wistar
(7–9 weeks old at start of dosing) rats, supplied by Charles River laboratories, USA.
Rats (n= 3) received a single intravenous (IV) bolus administration (1 mg/kg,
4 mL/kg, n= 3 rats) formulated as a solution in saline with the pH adjusted to 4.0.
Serial blood samples were collected by femoral artery sampling into tubes
containing an equal volume of water containing K2EDTA at various time points up
to 120 h post-dose.
Aliquots of diluted whole blood (50:50) were analysed using quantitative high-
performance liquid chromatography with tandem mass spectrometric detection
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(LC/MS/MS) following protein precipitation. All analytical runs met predefined
run acceptance criteria. PK parameters were generated following non-
compartmental analysis (Phoenix® WinNonlin® (Certara, L.P., St. Louis, MO)) of
the resulting concentration-time data.
Rat PK/PD studies: On arrival, all rats were housed in a plastic solid bottom
cage in groups of 2–3 with access to food and water ad libitum and under a 12 h
light–dark cycle. Male CD or Wistar Han rats (7–9 weeks old, Charles River UK
Ltd.) were randomly allocated to treatment groups upon arrival. Female CD rats
(7–8 weeks old on arrival, Charles River Ltd.) were placed into groups using a
randomization schedule based on body weight prior to the study start. All animals
were acclimatized for a minimum of one week prior to the experiment
commencing.
Subcutaneous PROTAC solution formulations were prepared on the day of
dosing as outlined below and filtered through a 0.22 µm Millex PVDF filter
(Millipore) prior to PROTAC administration. PROTAC 4 was dissolved in saline
with the pH adjusted to 5.0 with sodium hydroxide (1 M). PROTAC 6 and 7 were
dissolved in a vehicle of 25 mmol sodium acetate buffer in dextrose at pH 6.0 using
diluted acetic or dissolved in saline with the pH adjusted to 5.0 with sodium
hydroxide (1 M).
Blood samples were collected at selected time points post dose for
pharmacokinetic (PROTAC drug levels) measurements were diluted 50:50 with
purified water and 25 μl aliquots were analyzed using quantitative high-
performance liquid chromatography with tandem mass spectrometric detection
(LC/MS/MS) following protein precipitation. All analytical runs met predefined
run acceptance criteria.
Ex vivo stimulation of rat blood with L18-MDP for PD: PPD blood samples
taken prior to PROTAC administration or at fixed timepoints post PROTAC
administration through the course of the study, were treated ex vivo with
100 ng/mL L18-MDP (Invivogen) or vehicle (0.1% DMSO) and incubated for
4 h. Following centrifugation, plasma was collected for cytokines analysis as
detailed in cytokines assay section. Additionally, RIPK2 levels were determined
in PBMCs isolated from blood and where collected, in sampled colon tissue as
described in the text.
In vivo L18-MDP acute inflammation model. Following sub-cutaneous PROTAC
6 or 7 (0.3 mg/kg) or vehicle dosing, female rats received NOD2 pathway activation
by treatment with L18-MDP at 150 μg/rat via an intravenous injection at the
indicated timepoints. 2 h following L18-MDP challenge, rats were euthanized, and
terminal blood samples and tissues collected for cytokine analysis. Cytokine levels
were determined in serum generated from the terminal blood samples and in tissue
lysates as detailed below.
Isolation of rat peripheral blood mononuclear cells from blood. Blood was
mixed with optiPREP (Sigma) and following centrifugation at 1300 × g the PBMCs
layer was collected. For in vivo studies, RIPK2 levels were determined immediately
via immunoblotting, whereas for in vitro studies PBMCs were treated as detailed in
the in vitro treatment section.
Isolation of human PBMCs from blood for in vitro experiments. PBMCs were
isolated from leukodepletion filter from platelet aphaeresis supplied by National
Health System Blood and Transplant—NHSBT Apheresed at NHBST. The content
of each leukodepletion filter was diluted with phosphate buffered saline—PBS
(Gibco) and layered on top of HistoPaque 1077 (Sigma) and following cen-
trifugation at 800 g the resultant PBMCs ring was collected.
In vitro treatment of rat or human cells and blood. Before treatment with
compound or vehicle, THP1 cells, human and rat PBMCs were counted using Vi-
Cell cell counter (Invitrogen) and adjusted to a final cell density of 3–3.3 cell/ml
using complete growth medium. Cells or whole blood were treated with vehicle
(0.1% DMSO) or fixed concentrations of compound up to 1 μM in half log unit
increments and incubated for the time period indicated in the figure.
Where the assessment of cytokines was performed, L18-MDP was added to the
cell culture media (1 μg/ml) or to the rat blood samples (100 ng/ml) and samples
were incubated for up to 4 h. For human blood, 250 ng/ml MDP (Invivogen) was
added following compound treatment and the samples were further incubated for
5 h. Samples were them spun down at 1000 g and the cell culture supernatant,
plasma or serum were collected for cytokines assessment, while cell pellets were
used for RIPK2 and/or cIAP1, cIAP2, and XIAP levels analysis via
immunoblotting.
In vitro treatment of human tissue biopsy samples from CD and UC patients.
The human tissue samples were sourced ethically, and their research use was in
accord with the terms of the informed consents under an IRB/EC approved
protocol.
Colonic biopsies or tissues were obtained during endoscopy or via surgical
resection from Crohn’s Disease (CD) or Ulcerative Colitis (UC) patients (St
Bartholomew’s Hospital, London). All patients gave informed written consent. For
surgical specimens, the mucosa was dissected away from the submucosa and cut into
pieces of ~10–20mg. Samples were incubated for 24 h in serum free HL1 medium
(Lonza) containing 2mM L-glutamine, 100U/mL penicillin, 100 µg/mL streptomycin
and 10 µg/mL gentamicin and treated with either vehicle (0.1% DMSO), prednisolone
(1 µM) as a positive control, or PROTAC 6 (0.05–50 nM in log unit increments). The
supernatants were collected for cytokine measurement as detailed in cytokines assay
section while tissues were used to determine RIPK2 levels.
Determination of protein levels. Cells and tissue lysis: Cell pellets were resus-
pended in CelLytic M cell lysis buffer (Sigma) containing protease inhibitor
cocktail (Roche) while frozen rat tissues or UC and CD colon biopsies were ground
using a ball mill and the resulted powder was resuspended in RIPA buffer (Thermo
Scientific) with protease inhibitor cocktail. The samples were then spun down and
the supernatants were collected to use for RIPK2 and or IAPs levels analysis.
SDS-PAGE and immunoblotting: Samples were mixed with the lithium dodecyl
sulfate (LDS) sample buffer (Invitrogen) containing the reducing agent
(Invitrogen) and separated onto a 4–12% polyacrylamide gel (Invitrogen). Transfer
onto polyvinylidene difluoride (PVDF) Immobilon membranes (Millipore) was
performed using the Trans-Blot wet transfer unit (Bio-Rad) containing Tris-glycine
transfer buffer (25 mM Tris, pH 8.3 and 192 mM glycine) with 10% added
methanol. Membranes were blocked against non-specific binding with Odyssey
blocking buffer (Licor Bioscience), then incubated overnight with the anti-RIPK2
(1:500), followed by a 2 h incubation at room temperature with the antibody for the
loading control (1:10,000). Following washing in PBS containing 0.1% Tween 20,
membranes were incubated with anti-rabbit and anti-mouse IRdye secondary
antibodies (1:5000 dilution) 1 h at room temperature. The infrared signal was
detected using an Odyssey scanner CLX (Licor Biosciences) and densitometry was
performed using the Image Studio Lite version 5.2 software (Licor Biosciences).
The intensity of the infrared signal obtained with the RIPK2 antibody was
quantified and normalized relative to the intensity of control protein signal.
Simple Western immunoassay: Cell lysates were mixed with 5× concentrated
master mix (Protein Simple) and denatured at 95 °C on a heat block for 5 min
together with the provided ladder (Protein Simple). Antibodies were diluted in the
provided buffer as following: anti-RIPK2 (1:10 or 1:50), anti-cIAP1(1:10), anti-
cIAP2 (1:10), anti-XIAP (1:10), mouse anti-β-actin (Abcam - 1:1000), rabbit anti-
β-actin (Abcam - 1:50) and anti-vinculin (1:100). All reagents (blocking buffer,
primary and secondary antibodies, streptavadin, luminol/peroxide, separation
matrix, stacking matrix and water) were added to the Protein Simple plate
containing the ladder and lysates and the plate was placed in a Protein Simple
Western instrument and the Simple Western default size assay protocol was used.
All samples were analyzed using the associated Compass software 3.1.7. The area
under the peak values obtained for RIPK2, cIAP1, cIAP2 or XIAP were normalized
relative to the control protein values.
Cytokine measurement assay: Cytokine levels were measured in rat plasma or
rat PBMCs cell culture supernatants using rat V-Plex TNFα, in human plasma or
human PBMCs cell culture supernatants with either TNFα tissue culture or 7-plex
kit. Rat serum and tissues samples from the in vivo L18-MDP acute inflammation
model were analyzed using the rat TNFα, Il-6 and IL-8 U-Plex kits. All kits
provided by Meso Scale Discovery (MSD). Levels of cytokines spontaneously
released from human colon biopsies cell culture supernatants were measured using
Human IL-1 beta/IL-1F2 DuoSet ELISA (Bio-techne), Human IL-6 ELISA
(Immunotools) and Human TNF-alpha DuoSet ELISA (Bio-techne). All samples
were processed accordingly to the manufacturer’s instructions. The MSD plates
were analyzed using the MSD sector imager 6000 plate reader and cytokines
concentration (pg/ml) was obtained by using the MSD DISCOVERY
WORKBENCH software version 4.0.12.1
Statistics and reproducibility: All data were represented as percentage of the
control sample: DMSO treated cells for the in vitro assays and the pre-dose or
vehicle sample for the in vivo experiments.
In vitro experimental data were analyzed using a 4-parameter logistic equation
in GraphPad Prism 5.0.4. to generate an estimate of the half-maximal
concentration and maximal degradation, DC50 and Dmax value respectively, for
concentration-degradation relationships. Cytokine levels were analyzed in a similar
manner to yield IC50 and Imax values. The mean sigmoidal relationship is shown
superimposed on the data points displayed as mean ± s.e.m. Where analysis to a
sigmoidal relationship was not possible, the data points are shown as mean ± s.e.m.
For in vivo studies, RIPK2:tubulin ratios and cytokine levels from each
individual experiment were analysed either using a One-way ANOVA with
Dunnet’s post-test or a two way ANOVA using GraphPad Prism 5.0.4 to determine
statistical significance with 95% confidence levels.
Proteomics methods. Cell culture: THP-1 cell cultures (ATCC TIB-202, male)
were established in RPMI-based SILAC-L and SILAC-H medium. Cells were see-
ded in opposite SILAC label medium and incubated in presence of compounds or
vehicle (DMSO) for the indicated time points at 37 °C, 5% CO2. For harvesting, the
cells were washed in PBS, pelleted, and snap-frozen in liquid N2.
U87-MG cell cultures were established in in normal growth medium (DMEM,
10% dialyzed FBS, 5 ml NEAA, 5 ml sodium-pyruvate) or DMEM-based SILAC-L
and SILAC-H medium. Cells were seeded in opposite SILAC label medium and
incubated in presence of compounds or vehicle (DMSO) for the indicated time
points at 37 °C, 5% CO2. For harvesting, the cells were washed in PBS, pelleted, and
snap-frozen in liquid N2.
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Affinity enrichment chemoproteomics: In mPDP experiments affinity
enrichments were performed in lysates derived from PROTAC treated cells as
described previously28,29 by using kinobeads. Briefly, 100 μL (149 μg protein) cell
extract were incubated with kinobeads (3.5 μL beads per sample) for 1 h at 4 °C.
The beads were washed with lysis buffer and eluted with 20 μL 2× SDS sample
buffer and subjected to SDS gel electrophoresis. Samples were further processed for
LC-MS/MS analysis.
Affinity enrichment competition binding experiments were performed from
amino-functionalized compounds coupled to NHS activated Sepharose (GE
Healthcare) as described in H.C. Eberl et al. Chemical proteomics reveals target
selectivity of clinical Jak inhibitors in human primary cells (submitted), briefly one
milliliter of mixed lysate (HEK293/K-562/Placenta/U-87MG) (5 mg/mL protein
concentration) was incubated with the respective PROTAC for 45 min at 4 °C over
a range of concentrations followed by incubation with affinity matrix for 1 h. Beads
were washed, and eluted with 50 μL of a 2× SDS sample buffer and subjected to
SDS gel electrophoresis.
2D-TPP experiments, in cells: Experiments were performed as previously
described30. DMSO (vehicle), PROTAC dissolved in DMSO at indicated
concentrations were added to U87-MG cells (two plates for each concentration)
and incubated for 0.5, 1.5 or 4 h as indicated at 37 °C and 5% CO2. All following
steps were performed as previously described20. The heat treatment was done at 12
temperatures spread across a temperature range of 42.0–63.9 °C. Experiments were
analyzed as previously described29,30 and (https://www.cell.com/cell/fulltext/S0092-
8674(18)30174-0#secsectitle0070) with the exception that only proteins affected
reproducibly at two independent treatment durations were reported.
Mass spectrometry sample preparation: Sample preparation was performed as
described in (https://www.cell.com/cell/fulltext/S0092-8674(18)30174-
0#secsectitle0070), Briefly, gel lanes were cut into three slices covering the entire
separation range (∼2 cm) and subjected to in-gel tryptic digestion28. TMT labeling
was performed using the 10-plex TMT reagents, enabling relative quantification of
10 conditions in a single experiment. The labeling reaction was performed in
40 mM triethylammoniumbicarbonate, pH 8.53 at 22 °C and quenched with
glycine. Labeled peptide extracts were combined to a single sample per experiment.
Pre-fractionation was performed exactly as described by Savitski et al.32.
LC-MS analysis: Analysis was performed essentially as described by Savitski
et al.32.
Briefly, samples were dried in vacuo and resuspended in 0.05% trifluoroacetic
acid in water. Half of the sample was injected into an Ultimate3000 nanoRLSC
(Dionex, Sunnyvale, CA) coupled to a Q Exactive (Thermo Fisher Scientific).
Peptides were separated on custom-made 50 cm × 100 μm (ID) reversed-phase
columns (Reprosil) at 55 °C. Gradient elution was performed from 2% acetonitrile
to 40% acetonitrile in 0.1% formic acid and 3.5% DMSO over 2 h. Samples were
online injected into Q-Exactive mass spectrometers operating with a data-
dependent top 10 method. MS spectra were acquired by using 70,000 resolution
and an ion target of 3E6. Higher energy collisional dissociation (HCD) scans were
performed with 35% NCE at 35,000 resolution (at m/z 200), and the ion target
settings was set to 2E5 so as to avoid coalescence31.
Peptide and protein identification. Mascot 2.4 (Matrix Science, Boston, MA) was
used for protein identification by using a 10 parts per million mass tolerance for
peptide precursors and 20 mD (HCD) mass tolerance for fragment ions. The search
database consisted of a customized version of the International Protein Index protein
sequence database combined with a decoy version of this database created by using
scripts supplied by MatrixScience. In isobaric mass tag based experiments carbami-
domethylation of cysteine residues and TMT modification of lysine residues were set
as fixed modifications. Methionine oxidation, and N-terminal acetylation of proteins
and TMT modification of peptide N-termini were set as variable modifications.
Multiplexed pulsed SILAC isobaric mass tags searches for light and heavy SILAC were
performed independently. Carbamidomethylation of cysteine residues and TMT
modification of lysine residues were set as fixed modifications for the SILAC light
search. Carbamidomethylation, lysine 13C6 15N2 with TMT, and arginine 13C6 15N4
were set as fixed modifications in the heavy SILAC search. Methionine oxidation, N-
terminal acetylation of proteins and TMT modification of peptide N-termini were set
as variable modifications in both searches32.
Peptide and protein quantification. Reporter ion intensities were read from raw
data and multiplied with ion accumulation times (the unit is milliseconds) so as to
yield a measure proportional to the number of ions; this measure is referred to as
ion area42. Spectra matching to peptides were filtered according to the following
criteria: mascot ion score > 15, signal-to-background of the precursor ion > 4, and
signal-to-interference > 0.5. Fold changes were corrected for isotope purity as
described and adjusted for interference caused by co-eluting nearly isobaric peaks
as estimated by the signal-to-interference measure. Protein quantification was
derived from individual spectra matching to distinct peptides by using a sum-based
bootstrap algorithm; 95% confidence intervals were calculated for all protein fold
changes that were quantified with more than three spectra.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
The data underlying Figs. 1–6 is in the file Supplementary data 1. The raw data, including
blot images are available from the authors on reasonable request. The source data for the
proteomics plots in Fig. 7 are included in the files Supplementary data 2–4.
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